DiaMedica Therapeutics (NASDAQ:DMAC) Stock Falls 1.6% – Should You Sell?

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) dropped 1.6% on Monday. The company traded as low as $7.95 and last traded at $8.20. Approximately 185,580 shares traded hands during mid-day trading, a decline of 20% from the average session volume of 232,278 shares. The stock had previously closed at $8.33.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on DMAC. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Friday, July 17th. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of DiaMedica Therapeutics in a research report on Tuesday, August 11th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, DiaMedica Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

DiaMedica Therapeutics Trading Down 1.6%

The business’s 50 day moving average is $7.09 and its 200 day moving average is $6.68. The stock has a market capitalization of $442.23 million, a PE ratio of -11.39 and a beta of 0.92.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its earnings results on Monday, August 10th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. As a group, analysts anticipate that DiaMedica Therapeutics, Inc. will post -0.84 EPS for the current year.

Institutional Investors Weigh In On DiaMedica Therapeutics

Several institutional investors have recently added to or reduced their stakes in DMAC. Squarepoint Ops LLC acquired a new stake in DiaMedica Therapeutics during the 2nd quarter valued at approximately $1,023,000. Bank of New York Mellon Corp acquired a new position in DiaMedica Therapeutics in the second quarter valued at approximately $829,000. Sei Investments Co. grew its stake in shares of DiaMedica Therapeutics by 100.0% during the 1st quarter. Sei Investments Co. now owns 111,320 shares of the company’s stock worth $754,000 after purchasing an additional 55,660 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of DiaMedica Therapeutics during the 1st quarter worth about $356,000. Finally, Bank of America Corp DE grew its position in shares of DiaMedica Therapeutics by 62.5% during the 1st quarter. Bank of America Corp DE now owns 42,768 shares of the company’s stock valued at $290,000 after acquiring an additional 16,446 shares during the period. Institutional investors and hedge funds own 10.12% of the company’s stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious diseases affecting the kidneys and nervous system. The company’s research is centered on biological pathways that may support tissue protection and recovery in conditions with limited treatment options.

Its lead investigational product, DM199, is a recombinant form of human tissue kallikrein-1, an enzyme involved in the kallikrein-kinin system. DiaMedica has studied DM199 in acute ischemic stroke and kidney-related disorders, including severe acute kidney injury.